Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...
This approach collects a patient's T cells, engineers them to attack tumor cells and then injects the designer cells into the patient. "CAR T cells work well against hematological cancers like ...